Photo of E. Tom Richardson, MD, PhD

E. Tom Richardson, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8638
Fax: (617) 739-6192


ETRICHARDSON@BWH.HARVARD.EDU

Photo of E. Tom Richardson, MD, PhD

Brigham And Women's Hospital
Phone: (617) 732-8638
Fax: (617) 739-6192


ETRICHARDSON@BWH.HARVARD.EDU

Visualize Collaborations

E. Tom Richardson, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Instructor, Pathology, Harvard Medical School
  • Associate Pathologist, Pathology, Brigham And Women's Hospital

HCC PROGRAM AFFILIATION

Research Abstract

My major research interests are in breast cancer pathogenesis, molecular genetics, and understanding the tumor microenvironment in breast cancer. My research goals are to harness alterations in immune cell types and functions in breast cancer for development of predictive biomarkers and immunotherapies. My research will investigate these alterations in immune biomarkers, as well as pathologic data, in common and rare subtypes of breast cancer and their precursor lesions, to better predict individual responses and tailor therapies.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2020. PubMed
  • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer 2020; 6:19. PubMed
Visualize Collaborations